Our Team
Managing Director and Head of Japan
Vivian Liu
Vivian has over 20 years in operating and financing pharmaceutical companies, including C-level and Board of Directors positions at several private and Nasdaq companies. Vivian holds an MPA from the University of Southern California and a BA from UC Berkeley.
//Vivian Liu, Head of Corporate Affairs (left), and Eileen Kuida, Controller (right)
Eileen Kuida
Controller
Eileen has over 25 years of comprehensive experience in multi-country finance and operations leadership, including M&As, financial planning, analysis/reporting, and SOX compliance. Eileen holds an MBA from the University of Southern California and a BA from UC Berkeley.
Takashi Seto, MD
Head of Medical Affairs
Dr. Seto has over 25 years of experience in oncology research specializing in medical oncology for thoracic malignancies. Conducting clinical trials with new agents has been his primary focus for the past 15 years at the National Kyushu
Cancer Center. His tenure also includes Kumamoto Regional Medical Center and Tokai University Hospital. He joined PREMIA in September 2019 to focus on the development of precision medicine and targeted new drug therapies.
Dr. Seto is a member of the International Association for Study of Lung Cancer (IASLC, Board of Directors), the American Society for Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), and the Japan Society of Medical Oncology (JSMO, Councilor), and the Japan Lung Cancer Society (JLCS, Councilor). In 2005, Dr. Seto was involved with the revision of the JLCS Practice Guideline and from 2014 to 2018, served as Chief of Medical Oncology and Multidisciplinary Therapy. He is also an active member of the Japan Clinical Oncology Group (JCOG) and a member and board member of the West Japan Oncology Group (WJOG). Dr. Seto graduated from Kurume University School of Medicine in 1990.
Wenn Sun, Ph.D.
Founder and President
Wenn founded PREMIA in 2018 in collaboration with LCSCRUM leadership. Previously, Wenn was the Founder and Managing Partner for OxOnc Development, a venture company that, along with Pfizer Oncology, co-developed Xalkori in patients with ROS1 genetic alterations. Wenn was the head of Strategic Alliances for GSK Oncology, and helped build it's alliances with various clinical research networks in the world. She was appointed the Chief Business Development officer at the Lurie Cancer Center of Northwestern University after her post-doctoral fellowship at University of Wisconsin-Madison.
